» Download Public Reports
About 1 700 reports
- Company report
- April 2013
- 15 pages
- by Corporation
... Decreased from ~50% of the overall statin market to ~40% this year while the atorvastatin market has grown. It is because generic atorvastatin is taking the market share away from the innovator brand ...
April 2013
... Decreased from ~50% of the overall statin market to ~40% this year while the atorvastatin market has grown. It is because generic atorvastatin is taking the market share away from the innovator brand ...
April 2013
... The has been widely hailed as a victory for domestic manufactus, particularly generic drug producers. generic drugs are those that are introduced after patents expire on their original formulations ...
April 2013
... Raipur, chhattisgarh in collaboration with who, who, new delhi. 30/04/2013 The objectives To document the availability and price of key essential medicines for children in the state ...
April 2013
... The policy framework evolved thus far that are likely to affect the availability of drugs and their prices in the coming years. It also discusses issues such as liberalization of trade, investment ...
» Purchase Premium Reports
(From $ 125 - $ 6 995)
About 600 reports
- $ 6 995
- Industry report
- February 2013
- by Global Data
Evista (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Evista (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Reclast (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Forteo (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Protelos (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 4 995
PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis ...
March 2013
$ 4 995
PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market ...
May 2013
$ 5 174
This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in the top 10 global countries. The studies provide essential market information ...